Neuland Laboratories (Mid Cap - Potential Multibagger) Share Target 2026, 2027 To 2035
|
Neuland Laboratories Limited |
|||
|
Price: ₹17,056.00 (-0.83%) | ||
| 52 Week Low: ₹11,500.00 52 Week High: ₹19,747.00 |
|||
| Market Capital: 18,481.45 Crore (Mid-cap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Share Price HistoryNEULANDLAB FinancialsTomorrow TargetYearly TargetsDividend HistoryNo BonusNo Split
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Neuland Laboratories Share Price Target For 2026
- 1.1.1: Neuland Laboratories Share Price Target Table For 2026
- 1.1.2: Short-Term Technical Outlook
- 1.2: Neuland Laboratories Share Price Target For 2027
- 1.2.1: Neuland Laboratories Share Price Target Table For 2027
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Neuland Laboratories Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
- 3: Neuland Laboratories Brief Company Overview
- 4: Neuland Laboratories Financial Performance
- 4.0.1: Is Neuland Laboratories A Good Buy For Long Term?
Neuland Laboratories, a Mid Cap company in the Drug Manufacturers—Specialty & Generic Industry has delivered 756.3% returns in 5-year with 18.3% profit margin, making it a potential Multibagger.
To predict the Neuland Laboratories's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Neuland Laboratories Share Price Target For 2026
The line chart displays the monthly closing prices of Neuland Laboratories with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Neuland Laboratories shares in 2026, see the table below.
Neuland Laboratories Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 19623.34 (+15.05%) | Volatility: ATR T2 |
| 2026 Target 2 | 18596.41 (+9.03%) | Volatility: ATR T1 |
| 2026 Target 1 | 17264.35 (+1.22%) | Volatility: BB Upper |
| Current Price | 17056.00 | Neuland Laboratories's share price as of 15 Jun 2026 |
| Stop Loss 1 | 17017.34 (-0.23%) | Trend: EMA9 |
| Stop Loss 2 | 16596.65 (-2.7%) | 38.20% Weekly Fib Retrace |
| Stop Loss 3 | 16570.95 (-2.85%) | Volatility: BB Lower |
Short-Term Technical Outlook
Current Technical Position: Neuland Laboratories is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 50-day moving average at ₹16033.2 serves as the nearest technical reference point.
Historical Returns: 3-month: +39.46% | 6-month: +3.75% | 1-year: +30.36%
Neuland Laboratories Share Price Target For 2027
The line chart displays the monthly closing prices of Neuland Laboratories with a black line. The green line shows three potential target prices for 2027, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Neuland Laboratories shares in 2027, see the table below.
Neuland Laboratories Share Price Target Table For 2027
| Level | Value | Analysis |
|---|---|---|
| 2027 Target 3 | 19623.34 (+15.05%) | Volatility: ATR T2 |
| 2027 Target 2 | 18596.41 (+9.03%) | Volatility: ATR T1 |
| 2027 Target 1 | 17264.35 (+1.22%) | Volatility: BB Upper |
| Current Price | 17056.00 | Neuland Laboratories's share price as of 15 Jun 2026 |
| Stop Loss 1 | 17017.34 (-0.23%) | Trend: EMA9 |
| Stop Loss 2 | 16596.65 (-2.7%) | 38.20% Weekly Fib Retrace |
| Stop Loss 3 | 16570.95 (-2.85%) | Volatility: BB Lower |
Long-Term Technical Outlook
52-Week Range Analysis: Neuland Laboratories is currently trading at 67.4% of its 52-week range (₹11500 - ₹19747).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +30.36% | 3-year: +489.12% | 5-year: +756.32%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Neuland Laboratories Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹17,056.00 | ||
| 2026 | ₹22,669.09 | +32.90976782364% | ₹23,009.13 |
| 2027 | ₹29,953.39 | +32.133182231841% | ₹30,402.69 |
| 2028 | ₹43,227.96 | +44.317421166686% | ₹43,876.38 |
| 2029 | ₹64,183.40 | +48.476587838057% | ₹65,146.15 |
| 2030 | ₹94,893.41 | +47.847278268213% | ₹96,316.81 |
| 2031 | ₹128,744.84 | +35.673109439317% | ₹130,676.01 |
| 2032 | ₹177,321.07 | +37.730622835059% | ₹179,980.89 |
| 2033 | ₹229,366.79 | +29.351119976887% | ₹232,807.29 |
| 2034 | ₹324,817.54 | +41.61489551299% | ₹329,689.80 |
| 2035 | ₹436,318.84 | +34.327364218078% | ₹442,863.62 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Neuland Laboratories Brief Company Overview
Neuland Laboratories Limited: A Global Leader in API Manufacturing Overview: Neuland Laboratories Limited, established in 1984, is a renowned manufacturer of active pharmaceutical ingredients (APIs) Key Products and Services: APIs for diverse therapeutic areas including...
antiasthmatics, cardiovasculars, antifungal, anticonvulsants, CNS, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson Custom manufacturing solutions Peptide synthesis services Global Presence: Neuland Laboratories has a strong global footprint, operating in India, Europe, the United States, and internationally. Commitment: The company is committed to providing high-quality APIs and custom manufacturing solutions to its customers worldwide. Reputation: Neuland Laboratories Limited has established a strong reputation in the industry for its reliable manufacturing capabilities and diverse product range.Neuland Laboratories Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 20,002.13 Crore | Market valuation of Neuland Laboratories's shares. |
| Revenue (TTM) | 1,528.28 Crore | Total revenue generated by Neuland Laboratories over the past twelve months. |
| Net Income (TTM) | +279.66 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | 14.84% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | 18.29% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-25.6% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
-63.2% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
7.84 | Company's total debt divided by total shareholder equity. |
| Total Debt | 109.48 Crore | Sum of Neuland Laboratories's current & long-term financial obligations. |
| Total Cash | 190.36 Crore | Total amount of liquid funds available to Neuland Laboratories. |
| Beta | 0.98 | Beta is less than 1 indicating that the Neuland Laboratories's price is less volatile than the market. |
Is Neuland Laboratories A Good Buy For Long Term?
No valid response content found
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
